A226950 Stock Overview
Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
OliX Pharmaceuticals, Inc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩11,820.00 |
52 Week High | ₩25,950.00 |
52 Week Low | ₩8,280.00 |
Beta | 0.79 |
11 Month Change | -26.58% |
3 Month Change | -18.09% |
1 Year Change | -26.36% |
33 Year Change | -73.38% |
5 Year Change | -35.59% |
Change since IPO | -63.96% |
Recent News & Updates
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25Recent updates
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely
Apr 13Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year
Feb 17Shareholder Returns
A226950 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -6.0% | 1.5% | 1.9% |
1Y | -26.4% | 38.5% | 5.0% |
Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A226950 underperformed the KR Market which returned 5% over the past year.
Price Volatility
A226950 volatility | |
---|---|
A226950 Average Weekly Movement | 12.5% |
Biotechs Industry Average Movement | 9.5% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A226950's share price has been volatile over the past 3 months.
Volatility Over Time: A226950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 72 | Dong-Ki Lee | www.olixpharma.com |
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.
OliX Pharmaceuticals, Inc Fundamentals Summary
A226950 fundamental statistics | |
---|---|
Market cap | ₩200.63b |
Earnings (TTM) | -₩19.72b |
Revenue (TTM) | ₩17.90b |
11.2x
P/S Ratio-10.2x
P/E RatioIs A226950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A226950 income statement (TTM) | |
---|---|
Revenue | ₩17.90b |
Cost of Revenue | ₩222.79m |
Gross Profit | ₩17.68b |
Other Expenses | ₩37.40b |
Earnings | -₩19.72b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.16k |
Gross Margin | 98.76% |
Net Profit Margin | -110.18% |
Debt/Equity Ratio | 166.8% |
How did A226950 perform over the long term?
See historical performance and comparison